Evidence map›Paper›PMID 42201536›Full record

ArticleMolecular diversity2026

Identification of Closantel as a small-molecule inhibitor of the compact CRISPR-Cas RNA editor Cas13bt3.

Xulong Chen, Binbin Zhan, Ruyi Shi, Jingxuan Chen, Zhonghui Lin, Zuoan Li

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xulong Chen *College of Chemistry, Fuzhou University, Fuzhou, 350108, China.
Binbin Zhan *College of Chemistry, Fuzhou University, Fuzhou, 350108, China.
Ruyi Shi *College of Chemistry, Fuzhou University, Fuzhou, 350108, China.
Jingxuan ChenCollege of Chemistry, Fuzhou University, Fuzhou, 350108, China.
Zhonghui LinCollege of Chemistry, Fuzhou University, Fuzhou, 350108, China. zhonghui.lin@fzu.edu.cn.
Zuoan LiDepartment of Emergency, Fujian Provincial Key Laboratory of Emergency Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China. lizuoan@fzu.edu.cn.

Funding

National Natural Science Foundation of China 32471255Natural Science Foundation of Fujian Province 2024J02006
6 · The paper itself

Abstract

The type VI CRISPR-Cas systems are widely employed for programmable RNA editing, and the ultra-compact Cas13bt3 ribonuclease offers particular advantages for cellular delivery due to its minimal molecular size. However, its therapeutic potential is hindered by nonspecific collateral RNA cleavage activity and the lack of small-molecule inhibitors to enable spatiotemporal regulation of its function. Here, we performed a high-throughput screen for Cas13bt3 inhibitors using a fluorescence resonance energy transfer (FRET)-based RNA cleavage assay. From a library of 17,760 compounds, we identified Closantel as a specific Cas13bt3 inhibitor, with an IC

Indexed as

Cas13bt3CRISPR-CasHigh-throughput screeningRNA editingSmall-molecule inhibitor

Identifiers

PMID42201536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.